StreetAlpha.app
Home › Stocks › GOVX

GeoVax Labs, Inc. (GOVX)

$1.97
▼ −4.37%
LAST CLOSE · NOV 17

GeoVax develops vaccines and immunotherapies against infectious diseases and solid tumor cancers. It last closed at $1.97 on Nov 17, down 4.37% on the day.

AI Auto Pilots
Is GOVX in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$0
−100.0% vs a year ago
Net income
−$18.3M
Free cash flow
−$16.5M
Valuation
Market cap
$1.1M
544,453 shares
P/E
–
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$2.2M
At Sep 30
Shareholder equity
$1.1M
Shares outstanding
544,453
At Nov 12
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $386K$386KFY2021FY2022: $82K$82KFY2022FY2023: $0$0FY2023FY2024: $4.0M$4.0MFY2024FY2025: $2.5M$2.5MFY2025

From GOVX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 12). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated GOVX in the past 90 days, not enough for a consensus
Average 12-month target
$10.00
▲ 407.6% upside

Based on 1 analyst who set a price target on GOVX in the past 90 days. The average target is $10.00, with a high of $10.00 and a low of $10.00, compared with the last close of $1.97.

Low $10.00Avg $10.00High $10.00
Blue marker: last close $1.97
Highest target$10.00
Average target$10.00
Lowest target$10.00
Latest rating changes
Noble Capital MarketsMaintained
Sep 15Buy$10
DateFirmActionRatingPrice target
Sep 15Noble Capital MarketsMaintainedBuy$10
Loading…

Technical Analysis

GOVX · as of the Nov 17 close · updated after every close
Bounce inside a longer downtrend, overbought

The stock is 68% above its 20 day and 77% above its 50 day average. It is 42% above its 200 day average, so the longer trend is still up. Momentum is strong (RSI 77), overbought. The nearest support is the Pivot at $1.93, and the nearest resistance the Pivot R1 at $2.12.

Short trendBullish
Long trendBearish
MomentumStrong
StretchOverbought
VolatilityHigh, 14.7%/day
Key levels
$11.2852 week high+472.6%
$3.00Swing high (Nov 11)+52.3%
$2.12Pivot R1+7.6%
$1.97Last close
$1.93Pivot−2.0%
$1.78Pivot S1−9.6%
$1.17Swing low (Jun 24)−40.6%
$1.14200 day average−42.1%
$0.64100 day average−67.5%
$0.6320 day average−68.0%
$0.4550 day average−77.2%
$0.1152 week low−94.4%
Indicators
RSI (14)76.51Overbought above 70Overbought
MACD0.41Above its signal lineBullish
Stochastic62.3Middle of its rangeNeutral
ADX (14)45.7Strong uptrend
Williams %R-35.6Oversold below −80, overbought above −20Neutral
CCI (20)125.8Oversold below −100, overbought above 100Overbought
Rate of change+1100.5%Change over 10 sessionsBullish
ATR (14)$0.29Typical daily range, 14.7% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for GOVX

What happened before

See how GOVX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Whale Options Flow

90D

No whale options trades in GOVX in the last 90 days.

Loading…

See today’s whale options flow across the market →

GOVX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ●6 buying vs 6 selling
  • ▲Held by funds +1.8 pts
  • ▲Funds holding +2
  • ●No superinvestor moves
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding1917+11.8%
In funds' top 1000–
Held by funds92.4%90.6%+1.8 pts
New / increased4 / 25 / 3−25.0%
Reduced / sold out4 / 25 / 4−33.3%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See GOVX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether GOVX is in one of them and how their past GOVX trades turned out.

GOVX in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered GOVX in an article yet. Here's the latest on the wider market.

About GeoVax Labs

GeoVax is a biotechnology company based in Smyrna, Georgia, that develops vaccines and immunotherapies for infectious diseases and solid tumor cancers. Its lead near-term effort is a vaccine candidate against mpox and smallpox, intended to address supply shortages of orthopoxvirus vaccines for public health agencies and biodefense programs. The company also develops Gedeptin, a gene therapy for solid tumors including head and neck cancer, and a COVID-19 vaccine candidate for people with weakened immune systems.

Headquarters
Smyrna, GA